Bayer Aktienges Ads (BAYRY) 138.3900 $BAYRY
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
Bayer to Purchase Merck's Consumer Division - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 2:35PM CDT
Bayer (BAYRY) entered into a definitive agreement with Merck (MRK) to acquire the latter's consumer care business.
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Angina (Angina Pectoris) - Pipeline Review, H1 2014: 11 Company and 15 Drug Profiles
M2 - Wed May 07, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shfvfz/angina_angina) has announced the addition of the "Angina (Angina Pectoris) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardiolynx AG - Cardium Therapeutics, Inc. - Cheiljedang Corporation - Diakron Pharmaceuticals, Inc. - Juventas Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lacer, S.A. - Mesoblast Limited - Milestone Pharmaceuticals, Inc. - ViroMed Co., Ltd. Drug Profiles: - alferminogene tadenovec - VM-202 - VM-202 - CJ-30059 - ACP-01 - Organic Nitrate For Angina Pectoris - CLC-1201 - DP-3005 - JVS-100 - CEP-41750 - LA-8045 - MSP-2017 - BAY-606583 - KI-1007 - R-06 For more information visit http://www.researchandmarkets.com/research/sh...ina_angina
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Why Merck (MRK) Stock Is Falling In Pre-Market Trading Today
at The Street - Wed May 07, 8:25AM CDT
Merck (MRK) shares are down in pre-market trading after being downgraded to 'equalweight' by analysts at Morgan Stanley (MS) today.
Research and Markets: Global Textile Chemicals Market Report 2014-2018 Featuring Archroma GmbH, BASF SE, Bayer AG, Dow Chemical Co., and Huntsman Corp
Business Wire - Wed May 07, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqg6ds/global_textile) has announced the addition of the "Global Textile Chemicals Market 2014-2018" report to their offering.
Global Textile Chemicals Market Report 2014-2018 Featuring Archroma GmbH, BASF SE, Bayer AG, Dow Chemical Co., and Huntsman Corp
M2 - Wed May 07, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xwbnq2/global_textile) has announced the addition of the "Global Textile Chemicals Market 2014-2018" report to their offering. Traditional textile manufacturing consumes large amounts of energy, water, and chemicals, which is unsustainable and poses a threat to the environment. Chemical giants that manufacture textile chemicals are developing new products and technologies to enhance the sustainability of textile production. There is a rising demand for eco-friendly textiles and apparel in the Global Textiles market. Bio-auxiliaries, which are biodegradable and eco-friendly materials, are expected to bring in new solutions for textile wet processing. Using eco-friendly products also adds value to a manufacturer by differentiating its brand from competitors by eco-labeling. According to the report, one of the key drivers in the market is the increase in demand for finishing chemicals, which help in differentiating products by emphasizing product quality and enhancing comfort and durability. Further, the report states that one of the major challenges in this market is the growing environmental concern. Large quantities of hazardous chemicals are used in dyes and auxiliaries, which have adverse effects on the environment and are thus under the constant scrutiny of governments and environmentalists. Key vendors dominating this space are: - Archroma GmbH - BASF SE - Bayer AG - Dow Chemical Co. - Huntsman Corp. Other vendors mentioned in the report are: - Omnova Solutions Inc. - Sumitomo Chemical Co. Ltd. - Kiri Industries Ltd. - The Lubrizol Corp. - Huntsman Textile Effects Co. Ltd. - Pulcra Chemicals GmbH. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Product Type - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/xw...al_textile
Global Continuous Glucose Monitoring (CGMS) Market 2013-2019 - Analysis of the Major Devices/Brands
M2 - Wed May 07, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9j6w7/continuous) has announced the addition of the "Global Continuous Glucose Monitoring (CGMS) Market 2013-2019 - Analysis of the Major Devices/Brands" report to their offering. This report studies the current scenario as well as the future market potential for continuous glucose monitoring systems (CGMS) globally. The market for these CGMS has been segmented by major devices/brands, namely, Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus CGM System, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo System and others. The market for these systems has been extensively analyzed on the basis of factors such as their commercial launch, sales revenue, geographic presence, usage and technological developments. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2013 to 2019. Geographically, the continuous glucose monitoring market has been classified into four segments namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global continuous glucose monitoring market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The report concludes with the profiles of major players in the global continuous glucose monitoring market such as Medtronic, Inc., Dexcom, Inc., Abbott Laboratories, Inc., Bayer AG, Nova Biomedical Corporation, Senseonics, Incorporated, GlySens, Incorporated and Insulet Corporation. Scope Continuous Glucose Monitoring Market, by Device/Brand - Guardian Real Time CGM System - FreeStyle Navigator - Dexcom Seven Plus CGM System - Dexcom G4 Platinum - MiniMed Paradigm Revel/Veo System - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 - 2019 (USD Million) Chapter 5 Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/c9j6w7/continuous
Office Depot Jumps, but Whole Foods Market Slides After Hours
Jeremy Bowman, The Motley Fool - Motley Fool - Tue May 06, 9:00PM CDT
Stocks sank today as tensions in Ukraine heightened and some big names including AIG and Twitter fell, putting pressure on their respective sectors. The Dow Jones Industrial Average shed 130 points or 0.8% with drugmakers Merck and Pfizer ...
Merck: New drugs pending approval or in late tests
By LINDA A. JOHNSON - AP - Tue May 06, 6:02PM CDT
TRENTON, N.J. (AP) — Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.
Business Highlights
By The Associated Press - AP - Tue May 06, 4:43PM CDT
___
Regeneron Inks Ophthalmology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:20PM CDT
In a bid to boost its ophthalmology portfolio, Regeneron (REGN) inked a deal with Avalanche Biotechnologies.
Bayer to buy Merck consumer business for $14.2B
By LINDA A. JOHNSON - AP - Tue May 06, 4:07PM CDT
TRENTON, N.J. (AP) — Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet of household names from Bayer's aspirin to Merck's Claritin allergy pills.
Fitch: Merck Consumer Business Sale Improves Its Core Focus
Business Wire - Tue May 06, 2:05PM CDT
The sale of Merck's consumer products business will increase the company's focus on its core mission of developing and marketing innovative medicines, according to Fitch Ratings. German-based Bayer AG Tuesday said it planned to buy Merck's consumer health unit for $14.2 billion.
Bayer, Merck combining their medicine cabinets
By The Associated Press - AP - Tue May 06, 1:48PM CDT
Bayer AG's proposed purchase of Merck & Co.'s consumer health unit would create a combined over-the-counter business with many of the products in a typical medicine chest.
Merck, Pfizer Plunge to Lead the Dow's Triple-Digit Drop
Dan Carroll, The Motley Fool - Motley Fool - Tue May 06, 1:46PM CDT
Red has hit the market all over today, as the Dow Jones Industrial Average plunged into the red from the opening bell and hasn't looked back. As of 2:45 p.m. EDT, the average was down more than 104 points, with all but a select few blue-chip...
Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Tue May 06, 8:18AM CDT
Let's take a look at four stocks -- Bayer , Merck , Medivation , and AstraZeneca -- which could all make waves across the health care sector this Tuesday morning. Bayer acquires Merck's consumer care business for $14.2 billion ...
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
Bayer to Purchase Merck's Consumer Division - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 2:35PM CDT
Bayer (BAYRY) entered into a definitive agreement with Merck (MRK) to acquire the latter's consumer care business.
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Angina (Angina Pectoris) - Pipeline Review, H1 2014: 11 Company and 15 Drug Profiles
M2 - Wed May 07, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shfvfz/angina_angina) has announced the addition of the "Angina (Angina Pectoris) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardiolynx AG - Cardium Therapeutics, Inc. - Cheiljedang Corporation - Diakron Pharmaceuticals, Inc. - Juventas Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lacer, S.A. - Mesoblast Limited - Milestone Pharmaceuticals, Inc. - ViroMed Co., Ltd. Drug Profiles: - alferminogene tadenovec - VM-202 - VM-202 - CJ-30059 - ACP-01 - Organic Nitrate For Angina Pectoris - CLC-1201 - DP-3005 - JVS-100 - CEP-41750 - LA-8045 - MSP-2017 - BAY-606583 - KI-1007 - R-06 For more information visit http://www.researchandmarkets.com/research/sh...ina_angina
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Why Merck (MRK) Stock Is Falling In Pre-Market Trading Today
at The Street - Wed May 07, 8:25AM CDT
Merck (MRK) shares are down in pre-market trading after being downgraded to 'equalweight' by analysts at Morgan Stanley (MS) today.
Research and Markets: Global Textile Chemicals Market Report 2014-2018 Featuring Archroma GmbH, BASF SE, Bayer AG, Dow Chemical Co., and Huntsman Corp
Business Wire - Wed May 07, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqg6ds/global_textile) has announced the addition of the "Global Textile Chemicals Market 2014-2018" report to their offering.
Global Textile Chemicals Market Report 2014-2018 Featuring Archroma GmbH, BASF SE, Bayer AG, Dow Chemical Co., and Huntsman Corp
M2 - Wed May 07, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xwbnq2/global_textile) has announced the addition of the "Global Textile Chemicals Market 2014-2018" report to their offering. Traditional textile manufacturing consumes large amounts of energy, water, and chemicals, which is unsustainable and poses a threat to the environment. Chemical giants that manufacture textile chemicals are developing new products and technologies to enhance the sustainability of textile production. There is a rising demand for eco-friendly textiles and apparel in the Global Textiles market. Bio-auxiliaries, which are biodegradable and eco-friendly materials, are expected to bring in new solutions for textile wet processing. Using eco-friendly products also adds value to a manufacturer by differentiating its brand from competitors by eco-labeling. According to the report, one of the key drivers in the market is the increase in demand for finishing chemicals, which help in differentiating products by emphasizing product quality and enhancing comfort and durability. Further, the report states that one of the major challenges in this market is the growing environmental concern. Large quantities of hazardous chemicals are used in dyes and auxiliaries, which have adverse effects on the environment and are thus under the constant scrutiny of governments and environmentalists. Key vendors dominating this space are: - Archroma GmbH - BASF SE - Bayer AG - Dow Chemical Co. - Huntsman Corp. Other vendors mentioned in the report are: - Omnova Solutions Inc. - Sumitomo Chemical Co. Ltd. - Kiri Industries Ltd. - The Lubrizol Corp. - Huntsman Textile Effects Co. Ltd. - Pulcra Chemicals GmbH. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Product Type - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/xw...al_textile
Global Continuous Glucose Monitoring (CGMS) Market 2013-2019 - Analysis of the Major Devices/Brands
M2 - Wed May 07, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9j6w7/continuous) has announced the addition of the "Global Continuous Glucose Monitoring (CGMS) Market 2013-2019 - Analysis of the Major Devices/Brands" report to their offering. This report studies the current scenario as well as the future market potential for continuous glucose monitoring systems (CGMS) globally. The market for these CGMS has been segmented by major devices/brands, namely, Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus CGM System, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo System and others. The market for these systems has been extensively analyzed on the basis of factors such as their commercial launch, sales revenue, geographic presence, usage and technological developments. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2013 to 2019. Geographically, the continuous glucose monitoring market has been classified into four segments namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global continuous glucose monitoring market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The report concludes with the profiles of major players in the global continuous glucose monitoring market such as Medtronic, Inc., Dexcom, Inc., Abbott Laboratories, Inc., Bayer AG, Nova Biomedical Corporation, Senseonics, Incorporated, GlySens, Incorporated and Insulet Corporation. Scope Continuous Glucose Monitoring Market, by Device/Brand - Guardian Real Time CGM System - FreeStyle Navigator - Dexcom Seven Plus CGM System - Dexcom G4 Platinum - MiniMed Paradigm Revel/Veo System - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 - 2019 (USD Million) Chapter 5 Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/c9j6w7/continuous
Office Depot Jumps, but Whole Foods Market Slides After Hours
Jeremy Bowman, The Motley Fool - Motley Fool - Tue May 06, 9:00PM CDT
Stocks sank today as tensions in Ukraine heightened and some big names including AIG and Twitter fell, putting pressure on their respective sectors. The Dow Jones Industrial Average shed 130 points or 0.8% with drugmakers Merck and Pfizer ...
Merck: New drugs pending approval or in late tests
By LINDA A. JOHNSON - AP - Tue May 06, 6:02PM CDT
TRENTON, N.J. (AP) — Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.
Business Highlights
By The Associated Press - AP - Tue May 06, 4:43PM CDT
___
Regeneron Inks Ophthalmology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:20PM CDT
In a bid to boost its ophthalmology portfolio, Regeneron (REGN) inked a deal with Avalanche Biotechnologies.
Bayer to buy Merck consumer business for $14.2B
By LINDA A. JOHNSON - AP - Tue May 06, 4:07PM CDT
TRENTON, N.J. (AP) — Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet of household names from Bayer's aspirin to Merck's Claritin allergy pills.
Fitch: Merck Consumer Business Sale Improves Its Core Focus
Business Wire - Tue May 06, 2:05PM CDT
The sale of Merck's consumer products business will increase the company's focus on its core mission of developing and marketing innovative medicines, according to Fitch Ratings. German-based Bayer AG Tuesday said it planned to buy Merck's consumer health unit for $14.2 billion.
Bayer, Merck combining their medicine cabinets
By The Associated Press - AP - Tue May 06, 1:48PM CDT
Bayer AG's proposed purchase of Merck & Co.'s consumer health unit would create a combined over-the-counter business with many of the products in a typical medicine chest.
Merck, Pfizer Plunge to Lead the Dow's Triple-Digit Drop
Dan Carroll, The Motley Fool - Motley Fool - Tue May 06, 1:46PM CDT
Red has hit the market all over today, as the Dow Jones Industrial Average plunged into the red from the opening bell and hasn't looked back. As of 2:45 p.m. EDT, the average was down more than 104 points, with all but a select few blue-chip...
Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Tue May 06, 8:18AM CDT
Let's take a look at four stocks -- Bayer , Merck , Medivation , and AstraZeneca -- which could all make waves across the health care sector this Tuesday morning. Bayer acquires Merck's consumer care business for $14.2 billion ...
